EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access

Venetoclax and Azacitidine in the Treatment of NPM1 -Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review

Julie Ma iD, Kenji Morimoto, Michael A Pulsipher iD, Chintan Parekh

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00693 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Julie Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Fanconi Anemia, Leukemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy Agent DosageAzacitidine 75 mg/m 2 dose once daily on days 1-7 for first and second cycles Venetoclax 10 mg once on day 1 20 mg once on day 2 50 mg once on day 3 70 mg once daily on days 4-21 during the first cycle and days 4-14 during the second cycle JCO Precision Oncology ascopubs.org

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fanconi AnemiaLeukemiaHumansAzacitidineNuclear ProteinsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Substanzen

AzacitidineNuclear ProteinsvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
  • Department of Pediatrics, Kaiser Permanente Fontana Medical Center, Fontana, CA.
  • Division of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.

ORCID-Profile: Julie Ma, Michael A Pulsipher

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Ma, J., Morimoto, K., Pulsipher, M. A., & Parekh, C. (2023). Venetoclax and Azacitidine in the Treatment of NPM1 -Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review. JCO Precision Oncology. https://doi.org/10.1200/po.22.00693

Vancouver

Ma J, Morimoto K, Pulsipher MA, Parekh C. Venetoclax and Azacitidine in the Treatment of NPM1 -Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review. JCO Precision Oncology. 2023. doi:10.1200/po.22.00693

BibTeX
@article{Ma2023,
  author = {Ma, Julie and Morimoto, Kenji and Pulsipher, Michael A and Parekh, Chintan},
  title = {Venetoclax and Azacitidine in the Treatment of NPM1 -Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00693}
}
Kostenlos starten →